How Pharmaceutical Innovation is Saving the World

Published on: 

Viewpoint

Pharmaceutical Technology, Pharmaceutical Technology-02-02-2021, Volume 45, Issue 2
Pages: 10

Viewpoint: Mike Hennessy, Sr., founder and chairman of MJH Life Sciences, commends the leadership of the pharmaceutical industry in combatting the COVID-19 pandemic.

Editor's Note: This article was originally published online at PharmTech.com on Jan 6, 2021.

Nine months.

In March 2020, the United States was in the early stages of the COVID-19 pandemic. We shut the entire country down and ground the economy to a halt in an effort to slow the spread of the virus. Think back to March, and now much uncertainty we were living under.

Nine months later, FDA approved two COVID-19 vaccines under emergency authorization. Before New Year’s Day, millions of Americans had received the vaccine, including front-line physicians and health care providers and nursing home patients, our most vulnerable citizens.

Nine months. Take a moment to let that sink in.

The mainstream media has crafted a narrative around the COVID-19 pandemic that’s almost entirely negative. For the purpose of ratings, they have described the US response to the pandemic as blundering from one mistake to the next. This narrative is false.

There is another way—a more accurate and underappreciated way—to tell the story of the past nine months. It is a story of heroism, innovation, and precise science, performed under unbelievable pressure.

Let’s not mince words: The United States and the world needs to appreciate the role of the pharmaceutical industry—the researchers, physicians, and business leaders—who are rescuing the world from COVID-19. It’s the medical breakthrough of our lifetime.

Instead of dwelling on why many in the media are ignoring this, let’s review some facts:

Advertisement
  • Since the discovery of COVID-19, here is what scientists have accomplished: They identified a novel virus, unlocked and sequenced its genetic code, created new therapies to save lives, and developed multiple safe and effective vaccines using messenger RNA technology, a technology hopefully applicable to future vaccine development. Margaret Liu, MD, a member of the MJH Life Sciences COVID Coalition, called it a breakthrough for mRNA vaccines.
  • The United States has two vaccines approved for emergency use, one from Pfizer–BioNTech and another from Moderna, and the AstraZeneca/Oxford vaccine has been approved for emergency use in the United Kingdom. In addition, there are 64 vaccine candidates undergoing clinical trials at the moment, including 20 in Phase III trials. In the United States and around the world, the pharmaceutical industry has answered the call and invested heavily in this effort.
  • This was the fastest vaccine development program in history, and it’s not even close. David Pride, MD, a microbiologist at the University of California San Diego, estimates that vaccines typically take 10 to 15 years to develop. Until the COVID-19 pandemic, the fastest development timeline was four years, for the mumps vaccine.
  • Many government systems moved quickly to lessen the burden of onerous regulations and provide funding so that vaccines could be developed quickly but with still rigorous standards. Perhaps it should be a lesson to all of us that regulation/innovation can be calibrated more effectively during “normal” times as industry races to develop new therapies for our world’s other pandemics—cancer, diabetes, heart diseases, and more.

The next step of the process—distribution of the vaccine—will be as challenging as the development phase, if not more so. But again, the pharmaceutical industry is rising to the occasion. Factories around the world are working in overdrive to produce hundreds of millions of vaccine doses.

Already, less than a month after the Pfizer vaccine was approved, more than 15.4 million doses of vaccine have been distributed across the country, and more than 4.6 million people have received their first dose, according to Centers for Disease Control and Prevention (CDC) data. Many patients are already receiving their second dose.

While 15.4 million doses are impressive, some expected 20 million doses. But even that is moving the goal line a bit, as six months ago many observers didn’t think we’d get a vaccine until 2021.

Members of our COVID Coalition told us that the holidays slowed the rollout considerably. Nancy Messonnier, MD, a physician with the National Center for Immunization and Respiratory Diseases at the CDC, expects a rapid jump in administered vaccines during these first few days of 2021.

Every day, more people will be vaccinated. After health care workers and our most vulnerable citizens, other frontline workers will be next. Teachers will be vaccinated so our children can return to school. And soon, all Americans will be able to go to their doctor or walk into a CVS or Walgreens and receive the vaccine.

Remember, we did all this in nine months, with the help, dedication, and expertise of our pharmaceutical industry heroes. Next time you turn on the TV and see negativity, turn it off an imagine instead where we will be nine months from now.

About the Author

Mike Hennessy Sr is the founder and chairman of MJH Life Sciences.

Article Details

Pharmaceutical Technology
Vol. 45, No. 2
February 2021
Page: 10

Citation

When referring to this article, please cite it as M. Hennessy, Sr., "How Pharmaceutical Innovation is Saving the World," Pharmaceutical Technology 45 (2) 2021.